Lizzia Raffaghello

List of Publications by Year
in descending order

94 papers	7,024 citations	66315 42 h-index	60583 81 g-index
96 all docs	96 docs citations	96 times ranked	10470 citing authors

#	Article	IF	Citations
1	P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy. Pharmaceuticals, 2022, 15, 89.	1.7	11
2	Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors. Cancers, 2022, 14, 1802.	1.7	4
3	Comprehensive Phenotyping of Peripheral Blood T Lymphocytes in Healthy Mice. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 243-250.	1.1	8
4	Muscle inflammatory pattern in alpha- and gamma-sarcoglycanopathies. , 2021, 40, 310-318.		3
5	eATP/P2X7R Axis: An Orchestrated Pathway Triggering Inflammasome Activation in Muscle Diseases. International Journal of Molecular Sciences, 2020, 21, 5963.	1.8	11
6	The role of the P2X7 receptor in myeloid-derived suppressor cells and immunosuppression. Current Opinion in Pharmacology, 2019, 47, 82-89.	1.7	12
7	The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of Î±-Sarcoglycanâ€“Deficient Muscular Dystrophy. American Journal of Pathology, 2019, 189, 354-369.	1.9	9
8	Immune Adjuvants and Cytokine Therapies. , 2018, , 243-257.		0
9	Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. OncoImmunology, 2018, 7, e1378843.	2.1	88
10	Effect of starvation on brain glucose metabolism and 18F-2-fluoro-2-deoxyglucose uptake: an experimental in-vivo and ex-vivo study. EJNMMI Research, 2018, 8, 44.	1.1	14
11	Curcumin induces a fatal energetic impairment in tumor cells in vitro and in vivo by inhibiting ATP-synthase activity. Carcinogenesis, 2018, 39, 1141-1150.	1.3	37
12	Mesenchymal stromal cells and autoimmunity. International Immunology, 2017, 29, 49-58.	1.8	61
13	Use of luciferase probes to measure ATP in living cells and animals. Nature Protocols, 2017, 12, 1542-1562.	5.5	149
14	Metabolic Alterations at the Crossroad of Aging and Oncogenesis. International Review of Cell and Molecular Biology, 2017, 332, 1-42.	1.6	16
15	Targeting ofPHOX2Bexpression allows the identification of drugs effective in counteracting neuroblastoma cell growth. Oncotarget, 2017, 8, 72133-72146.	0.8	8
16	Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Oncotarget, 2016, 7, 2968-2984.	0.8	57
17	Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt. Scientific Reports, 2016, 6, 25092.	1.6	67
18	Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. Scientific Reports, 2016, 6, 19569.	1.6	43

#	Article	IF	Citations
19	Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor. World Journal of Gastroenterology, 2016, 22, 3496-3501.	1.4	3
20	Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models. Oncotarget, 2015, 6, 11806-11819.	0.8	127
21	Cancer associated fibroblasts in hematological malignancies. Oncotarget, 2015, 6, 2589-2603.	0.8	46
22	Accelerated Tumor Progression in Mice Lacking the ATP Receptor P2X7. Cancer Research, 2015, 75, 635-644.	0.4	157
23	The P2X7 receptor is a key modulator of the PI3K/GSK3Î²/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene, 2015, 34, 5240-5251.	2.6	149
24	Classification and biology of tumour associated stromal cells. Immunology Letters, 2015, 168, 175-182.	1.1	34
25	Dysregulated metabolism contributes to oncogenesis. Seminars in Cancer Biology, 2015, 35, S129-S150.	4.3	225
26	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
27	ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death and Disease, 2014, 5, e1135-e1135.	2.7	102
28	Unveiling the role of TNF â€Î± in mesenchymal stromal cellâ€mediated immunosuppression. European Journal of Immunology, 2014, 44, 352-356.	1.6	10
29	Potentiation of crizotinib activity by fasting cycles in an ALK+ lung cancer model.. Journal of Clinical Oncology, 2014, 32, e13511-e13511.	0.8	2
30	Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. Oncotarget, 2014, 5, 10368-10381.	0.8	18
31	Myeloid-Derived Suppressor Cells and Tumor Growth. , 2014, , 91-109.		2
32	CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. Neuropharmacology, 2013, 75, 337-346.	2.0	25
33	Mechanisms of the Antitumor Activity of Human VÎ³9VÎ´2 T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma. Molecular Therapy, 2013, 21, 1034-1043.	3.7	47
34	Immunosuppressive Microenvironment in Neuroblastoma. Frontiers in Oncology, 2013, 3, 167.	1.3	61
35	Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity. Journal of Leukocyte Biology, 2013, 94, 183-191.	1.5	13
36	Proteome Profiling of Neuroblastoma-Derived Exosomes Reveal the Expression of Proteins Potentially Involved in Tumor Progression. PLoS ONE, 2013, 8, e75054.	1.1	122

#	Article	IF	Citations
37	MYCN: from oncoprotein to tumor-associated antigen. Frontiers in Oncology, 2012, 2, 174.	1.3	16
38	Expression of P2X7 Receptor IncreasesIn VivoTumor Growth. Cancer Research, 2012, 72, 2957-2969.	0.4	324
39	Structureâ€“activity relationships of novel substituted naphthalene diimides as anticancer agents. European Journal of Medicinal Chemistry, 2012, 57, 417-428.	2.6	44
40	Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy. Science Translational Medicine, 2012, 4, 124ra27.	5.8	531
41	Starvation, detoxification, and multidrug resistance in cancer therapy. Drug Resistance Updates, 2012, 15, 114-122.	6.5	52
42	Close Interactions between Mesenchymal Stem Cells and Neuroblastoma Cell Lines Lead to Tumor Growth Inhibition. PLoS ONE, 2012, 7, e48654.	1.1	23
43	Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke. Current Pharmaceutical Biotechnology, 2012, 13, 59-67.	0.9	7
44	Cytokines in neuroblastoma: from pathogenesis to treatment. Immunotherapy, 2011, 3, 895-907.	1.0	23
45	Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. PLoS ONE, 2011, 6, e22739.	1.1	68
46	Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunology, Immunotherapy, 2011, 60, 1485-1495.	2.0	21
47	Damageâ€associated molecular patterns (DAMPs) and mesenchymal stem cells: A matter of attraction and excitement. European Journal of Immunology, 2011, 41, 1828-1831.	1.6	22
48	Disclosing the mysteries of the central nervous system sanctuary for acute lymphoblastic leukemia cells. Leukemia Research, 2011, 35, 699-700.	0.4	3
49	Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Research, 2011, 21, 1470-1486.	5.7	66
50	Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression. PLoS ONE, 2010, 5, e9024.	1.1	35
51	Fasting and differential chemotherapy protection in patients. Cell Cycle, 2010, 9, 4474-4476.	1.3	102
52	Reduced Levels of IGF-I Mediate Differential Protection of Normal and Cancer Cells in Response to Fasting and Improve Chemotherapeutic Index. Cancer Research, 2010, 70, 1564-1572.	0.4	245
53	Potential of mesenchymal stem cells for the therapy of autoimmune diseases. Expert Review of Clinical Immunology, 2010, 6, 211-218.	1.3	33
54	Systemic and Intraplaque Mediators of Inflammation Are Increased in Patients Symptomatic for Ischemic Stroke. Stroke, 2010, 41, 1394-1404.	1.0	106

#	Article	IF	Citations
55	A Novel Mechanism of Soluble HLA-G Mediated Immune Modulation: Downregulation of T Cell Chemokine Receptor Expression and Impairment of Chemotaxis. PLoS ONE, 2010, 5, e11763.	1.1	43
56	Editorial: In-and-out blood vessels: new insights into T cell reverse transmigration. Journal of Leukocyte Biology, 2009, 86, 1271-1273.	1.5	1
57	Chemokines in neuroectodermal tumour progression and metastasis. Seminars in Cancer Biology, 2009, 19, 97-102.	4.3	26
58	Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. European Journal of Paediatric Neurology, 2009, 13, 219-223.	0.7	54
59	CX3CR1 Is Expressed by Human B Lymphocytes and Meditates CX3CL1 Driven Chemotaxis of Tonsil Centrocytes. PLoS ONE, 2009, 4, e8485.	1.1	40
60	Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens. Stem Cells, 2008, 26, 1275-1287.	1.4	134
61	Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma. Free Radical Biology and Medicine, 2008, 44, 474-482.	1.3	70
62	Human Mesenchymal Stem Cells Inhibit Neutrophil Apoptosis: A Model for Neutrophil Preservation in the Bone Marrow Niche. Stem Cells, 2008, 26, 151-162.	1.4	442
63	Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8215-8220.	3.3	471
64	Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase. PLoS ONE, 2008, 3, e2599.	1.1	546
65	Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release. Cancer Research, 2007, 67, 6433-6441.	0.4	100
66	Expression and Functional Analysis of Human Leukocyte Antigen Class I Antigen-Processing Machinery in Medulloblastoma. Cancer Research, 2007, 67, 5471-5478.	0.4	33
67	CXCL12 Does Not Attract CXCR4+ Human Metastatic Neuroblastoma Cells: Clinical Implications. Clinical Cancer Research, 2006, 12, 77-82.	3.2	47
68	In vitro and In vivo Antitumor Activity of the Novel Derivatized Polyvinyl Alcohol-Based Polymer P10(4). Clinical Cancer Research, 2006, 12, 3485-3493.	3.2	13
69	The P2X7 Receptor Sustains the Growth of Human Neuroblastoma Cells through a Substance Pâ€“Dependent Mechanism. Cancer Research, 2006, 66, 907-914.	0.4	137
70	Immunotherapy of neuroblastoma: present, past and future. Expert Review of Neurotherapeutics, 2006, 6, 509-518.	1.4	1
71	Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene, 2005, 24, 4634-4644.	2.6	92
72	Mechanisms of immune evasion of human neuroblastoma. Cancer Letters, 2005, 228, 155-161.	3.2	76

#	Article	IF	Citations
73	Reactive oxygen species: Biological stimuli of neuroblastoma cell response. Cancer Letters, 2005, 228, 111-116.	3.2	27
74	CCL19 and CXCL12 Trigger in Vitro Chemotaxis of Human Mantle Cell Lymphoma B Cells. Clinical Cancer Research, 2004, 10, 964-971.	3.2	64
75	Heterogeneous Expression of Interleukin-18 and Its Receptor in B-Cell Lymphoproliferative Disorders Deriving from Naive, Germinal Center, and Memory B Lymphocytes. Clinical Cancer Research, 2004, 10, 144-154.	3.2	32
76	Immunogenicity of Human Neuroblastoma. Annals of the New York Academy of Sciences, 2004, 1028, 69-80.	1.8	48
77	Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma. Neoplasia, 2004, 6, 558-568.	2.3	216
78	Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2. International Journal of Molecular Medicine, 2004, 14, 383-8.	1.8	9
79	Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 442, 555-562.	1.4	68
80	In vitro andin vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma. International Journal of Cancer, 2003, 104, 559-567.	2.3	41
81	Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. Journal of Cellular Biochemistry, 2003, 89, 698-708.	1.2	33
82	Biological and clinical role of p73 in neuroblastoma. Cancer Letters, 2003, 197, 111-117.	3.2	19
83	Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Letters, 2003, 197, 151-155.	3.2	36
84	Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Letters, 2003, 197, 205-209.	3.2	37
85	Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Letters, 2003, 197, 181-184.	3.2	20
86	Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. British Journal of Cancer, 2003, 88, 1527-1536.	2.9	31
87	In vivo angiogenic activity of neuroblastoma correlates withMYCN oncogene overexpression. International Journal of Cancer, 2002, 102, 351-354.	2.3	52
88	Inhibition of neuroblastoma-induced angiogenesis by fenretinide. International Journal of Cancer, 2001, 94, 314-321.	2.3	63
89	Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects. Journal of the National Cancer Institute, 2000, 92, 253-261.	3.0	98
90	N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cellsInVitro through induction of programmed cell death. , 1999, 81, 262-267.		28

#	Article	IF	Citations
91	GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. , 1999, 81, 268-274.		57
92	Anti Gd2-Immunoliposome-Mediated Targeting of [125I] Metaiodobenzylguanidine to Neuroblastoma and Melanoma Cells in Vitro. Journal of Liposome Research, 1999, 9, 367-385.	1.5	5
93	Induction of differentiation and apoptosis by interferon-Î³ in human neuroblastoma cells in vitro as a dual and alternative early biological response. Cell Death and Differentiation, 1997, 4, 150-158.	5.0	10
94	Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. , 1996, 67, 95-100.		22